Tendon Injuries
Conditions
Keywords
Muscle function, Muscle damage and recovery, Eccentric exercise, Muscle soreness, Protein synthesis
Brief summary
An isolated bout of unaccustomed maximal eccentric exercise is associated with muscle force loss for 2-4 days, mild reversible muscle tenderness, and ultra-structural damage to the muscle fibers, elevation of muscle proteins in serum, and a detriment in range of motion. This single center, pilot study is designed to optimize conditions for the robust measurement of functional deficits after muscle damage and to identify markers of repair over 22 days to inform future intervention studies. The primary measure will be limb force (assessed electronically from the ergometer), previous studies have demonstrated that functional measures return fairly rapidly, usually between 2-4 days. Additionally, several biomarkers of muscle function will be measured over 22 days, as well as changes in protein synthesis in biopsy samples Deuterium-labelled water (D2O) will be consumed by all study participants from Day-3 through Day 22 to aid in quantifying newly synthesized proteins.
Interventions
OTHEREccentric exercise
Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Males aged between 18 and 35 years of age inclusive, at the time of signing the informed consent, not on a regular exercise program. * Body Mass Index (BMI) 18-27 kilogram per meter square (kg/m\^2) with waist circumference \<96 centimeter (cm). * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or
Exclusion criteria
, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. * Based on single or averaged corrected QT interval (QTc) (Bazzett \[QTcB\] or Fredericia \[QTcF\]) values of triplicate electrocardiograms (ECGs) obtained over a brief recording period: QTc \<450 milliseconds (msec); or QTc \< 480 msec in subjects with Bundle Branch Block. * At least a 1year history of no regular (2-3 times per week) exercise and no heavy exertion within past week.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change and percent change in maximal leg isometric strength from the baseline up to three weeks after eccentric exercise | Day 1, 2, 3, 4, 6, 8, 11, 17 and Day 22 | Muscle strength is a measure the amount of force produced during a maximal voluntary contraction. Strength will be assessed by a maximal isometric (fixed length) contraction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in peak torque and total work performed over the course of 10 consecutive, maximal isokinetic knee extension and flexion contractions | Day 1, 2, 3, 4, 6, 8, 11, 17 and Day 22 | Each subject will be asked to produce 10 consecutive, maximal isokinetic knee extension and flexion contractions through the full range of motion with the exercised leg on an ergometer |
| Patient pain assessment using a visual analog scale | Day 1, 2, 3, 4, 6, 8, 11, 17 and Day 22 | Leg pain will be assessed for the exercised leg with a visual analog scale (0-100 mm) before and up to three weeks after eccentric exercise |
| Change in degree of motion | Day 1, 2, 3, 4, 6, 8, 11, 17 and Day 22 | Each subject will be asked to attempt to move the exercised leg through a full range of motion with zero resistance from baseline up to three weeks after eccentric exercise |
| Change in plasma CPK and aldolase | Day 1, 2, 3, 4, 6, 8, 11, 17 and Day 22 | Blood sample will be collected to assess CPK and aldolase from baseline and up to three weeks after eccentric exercise |
| Change in plasma markers | Day 1, 2, 3, 4, 6, 8, 11, 17 and Day 22 | Blood sample will be collected to assess blood inflammatory markers including, but are not limited to, tissue necrosis factor alpha (TNFalpha), interleukin (IL) 1 beta, IL6, IL8, IL10, chemokine ligand (CCL)7, complement 3a (C3a), granulocyte macrophage colony stimulating factor (GM-CSF), and c-reactive protein (CRP) from baseline and up to three weeks after eccentric exercise |
Countries
United Kingdom
Outcome results
None listed